Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.05.15	Press Release: Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA (Dow Jones)
21.05.15	Press Release: Novartis drug Afinitor(R) extended -2- (Dow Jones)
21.05.15	Press Release: Novartis drug Afinitor(R) extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors (Dow Jones)
20.05.15	Press Release: Novartis announces two positive US -2- (Dow Jones)
20.05.15	Press Release: Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 (Dow Jones)
08.05.15	Press Release: Novartis lung cancer drug -2- (Dow Jones)
08.05.15	Press Release: Novartis lung cancer drug Zykadia(R) gains EU approval, providing new therapy for certain patients with ALK+ NSCLC (Dow Jones)
27.04.15	Press Release: Novartis announces Phase III study -2- (Dow Jones)
27.04.15	Press Release: Novartis announces Phase III study of Arzerra(R) met primary endpoint of improved progression-free survival in patients with relapsed CLL (Dow Jones)
23.04.15	Press Release: Novartis delivered sales growth -5- (Dow Jones)
23.04.15	Press Release: Novartis delivered sales growth -4- (Dow Jones)
23.04.15	Press Release: Novartis delivered sales growth -3- (Dow Jones)
23.04.15	Press Release: Novartis delivered sales growth -2- (Dow Jones)
23.04.15	Press Release: Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio (Dow Jones)
21.04.15	Press Release: Novartis: Data at AAN showed -2- (Dow Jones)
21.04.15	Press Release: Novartis: Data at AAN showed Gilenya(R) high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS pa... (Dow Jones)
16.04.15	Press Release: Sandoz receives FDA approval for -2- (Dow Jones)
16.04.15	Press Release: Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone(R) 20mg (Dow Jones)
16.04.15	Press Release: Novartis: Alcon receives FDA -2- (Dow Jones)
16.04.15	Press Release: Novartis: Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States (Dow Jones)
15.04.15	Press Release: Data in The Lancet show Novartis -2- (Dow Jones)
15.04.15	Press Release: Data in The Lancet show Novartis drug Arzerra(R) plus chlorambucil improved median progression-free survival by 71% in CLL patients (Dow Jones)
13.04.15	Press Release: Gilenya(R) data at AAN to -2- (Dow Jones)
13.04.15	Press Release: Gilenya(R) data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians (Dow Jones)
31.03.15	Press Release: Novartis announces FDA approval -2- (Dow Jones)
31.03.15	Press Release: Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload (Dow Jones)
30.03.15	Press Release: Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group (Dow Jones)
21.03.15	Press Release: Novartis' Cosentyx(TM) two-year -2- (Dow Jones)
21.03.15	Press Release: Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients (Dow Jones)
20.03.15	Press Release: New Novartis data shows -2- (Dow Jones)
20.03.15	Press Release: New Novartis data shows Cosentyx(TM) is significantly superior to Stelara(R) and clears skin (PASI 90) in nearly 80% of psoriasis patients (Dow Jones)
17.03.15	Press Release: Novartis receives EU approval for -2- (Dow Jones)
17.03.15	Press Release: Novartis receives EU approval for Jakavi(R) in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer (Dow Jones)
13.03.15	Press Release: Novartis to present new -2- (Dow Jones)
13.03.15	Press Release: Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skin (Dow Jones)
06.03.15	Press Release: Novartis: FDA approves first -2- (Dow Jones)
06.03.15	Press Release: Novartis: FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz (Dow Jones)
02.03.15	GlobeNewswire/Novartis annonce la conclusion des -2- (Dow Jones)
02.03.15	GlobeNewswire/Novartis annonce la conclusion des transactions avec GSK (Dow Jones)
02.03.15	GlobeNewswire/Novartis gibt Abschluss von -2- (Dow Jones)
27.02.15	Press Release: Novartis: Positive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degeneration (Dow Jones)
27.02.15	GlobeNewswire/Aktionäre genehmigen alle Anträge -2- (Dow Jones)
27.02.15	GlobeNewswire/Aktionäre genehmigen alle Anträge des Verwaltungsrats von Novartis (Dow Jones)
27.02.15	Press Release: Novartis shareholders approve all resolutions proposed by Novartis Board of Directors (Dow Jones)
27.02.15	GlobeNewswire/Les actionnaires de Novartis -2- (Dow Jones)
27.02.15	GlobeNewswire/Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration (Dow Jones)
27.02.15	Press Release: Novartis lung cancer drug -2- (Dow Jones)
27.02.15	Press Release: Novartis lung cancer drug Zykadia(R) recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib (Dow Jones)
23.02.15	Press Release: Novartis receives FDA approval of -2- (Dow Jones)
23.02.15	Press Release: Novartis receives FDA approval of Farydak(R), the first HDAC inhibitor for patients with multiple myeloma (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert